Lv4
530 积分 2026-04-17 加入
In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?
2个月前
已完结
Recaticimab: First Approval
2个月前
已完结
Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study
2个月前
已完结
Recaticimab as Add-On Therapy to Statins for Nonfamilial Hypercholesterolemia: The Randomized, Phase 3 REMAIN-2 Trial
2个月前
已完结
Recaticimab Monotherapy for Nonfamilial Hypercholesterolemia and Mixed Hyperlipemia: The Phase 3 REMAIN-1 Randomized Trial
2个月前
已完结
In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?
2个月前
已完结
Early Initiation of PCSK9 Inhibitor Therapy Versus Placebo in Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis
2个月前
已完结
Strike early–strike strong lipid-lowering strategy with proprotein convertase subtilisin/kexin type 9 inhibitors in acute coronary syndrome patients: real-world evidence from the AT-TARGET-IT registry
2个月前
已完结
Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction
2个月前
已完结
皖公网安备34019202002308
